Literature DB >> 22119384

Dose-dependent cardioprotection of enkephalin analogue Eribis peptide 94 and cardiac expression of opioid receptors in a porcine model of ischaemia and reperfusion.

Lars O Karlsson1, Niklas Bergh, Lizhen Li, Erik Bissessar, Irina Bobrova, Garrett J Gross, Levent M Akyürek, Lars Grip.   

Abstract

Opioids confer cardioprotection after myocardial ischaemia and reperfusion. The primary aim of the present study was to evaluate the cardioprotective effect of different doses of enkephalin analogue Eribis peptide 94 (EP 94) in a porcine model of ischaemia and reperfusion. A secondary aim was to analyse the impact of ischaemia and reperfusion on the expression of opioid receptor subtypes in the porcine heart. Thirty-four anesthetised pigs underwent 40 min of balloon occlusion of the left anterior descending coronary artery followed by four hours of reperfusion. Pigs were given either vehicle (0.9% NaCl) or one of four doses of EP 94 (0.2, 1, 5 or 25 ug/kg at each administration, respectively), intravenously after 26, 33 and 40 min of ischaemia. Hearts were stained to quantify area at risk and infarct size. mRNA and protein expressions of the opioid receptor subtypes were detected with RT-PCR, immunoblotting and immunohistochemistry in the control and ischaemic/reperfused areas. There was a significant dose-response relationship between higher doses of EP 94 and reduced infarct size. Expression of κ- and δ-opioid receptors was detected at both mRNA and protein levels. In ischaemic/reperfused areas, an increased expression of mRNA for both receptors was observed, whereas only protein expression for the δ subtype was up-regulated. The μ-opioid receptor was not detected.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119384     DOI: 10.1016/j.ejphar.2011.11.012

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

2.  Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury.

Authors:  Jianxun Liu; Hua Zhu; Yongqiu Zheng; Zhaobin Xu; Lei Li; Tao Tan; Ki Ho Park; Jincai Hou; Cuixiang Zhang; Dan Li; Ran Li; Zhenguo Liu; Noah Weisleder; Desheng Zhu; Peihui Lin; Jianjie Ma
Journal:  J Mol Cell Cardiol       Date:  2014-12-20       Impact factor: 5.000

Review 3.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

4.  The differential effects of a selective kappa-opioid receptor agonist, U50488, in guinea pig heart tissues.

Authors:  Chi-Feng Hung; Hsin-Ju Li; Hsun-Hao Chang; Gon-Ann Lee; Ming Jai Su
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

Review 5.  Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection.

Authors:  Zesergio Melo; Cecilia Ishida; Maria de la Paz Goldaraz; Rocio Rojo; Raquel Echavarria
Journal:  Noncoding RNA       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.